• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 6:18:58 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRDF alert in real time by email
    SC 13G 1 d100462dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. _)*

     

     

    Cardiff Oncology, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    14147L108

    (CUSIP Number)

    December 31, 2020

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    SCHEDULE 13G

    CUSIP No.     14147L108

     

      1    

      Names of reporting persons

     

      Corriente Advisors, LLC

      2  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC use only

     

      4  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       5     

      Sole voting power

     

      0

       6   

      Shared voting power

     

      2,000,000 (1)

       7   

      Sole dispositive power

     

      0

       8   

      Shared dispositive power

     

      2,000,000 (1)

      9    

      Aggregate amount beneficially owned by each reporting person

     

      2,000,000

    10  

      Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

      ☐

    11  

      Percent of class represented by amount in Row (9)

     

      5.66% (2)

    12  

      Type of reporting person (see instructions)

     

      OO

     

    (1)

    Consists of 2,000,000 shares of common stock of the Issuer, par value $0.0001 per share (“Shares”), directly held by Corriente Master Fund II, LP as of the date hereof. Corriente Advisors, LLC acts as an investment adviser to, and manages investment and trading accounts of, Corriente Master Fund II, LP. Corriente Advisors, LLC may be deemed to indirectly beneficially own securities held by Corriente Master Fund II, LP.

    (2)

    Based on 35,324,607 Shares outstanding as of October 30, 2020, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2020.

     

    2


    CUSIP No.    14147L108

     

      1    

      Names of reporting persons

     

      Corriente Master Fund II, LP

      2  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC use only

     

      4  

      Citizenship or place of organization

     

      Cayman Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       5     

      Sole voting power

     

      0

       6   

      Shared voting power

     

      2,000,000 (1)

       7   

      Sole dispositive power

     

      0

       8   

      Shared dispositive power

     

      2,000,000 (1)

      9    

      Aggregate amount beneficially owned by each reporting person

     

      2,000,000

    10  

      Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

      ☐

    11  

      Percent of class represented by amount in Row (9)

     

      5.66% (2)

    12  

      Type of reporting person (see instructions)

     

      PN

     

    (1)

    Consists of 2,000,000 shares of common stock of the Issuer, par value $0.0001 per share (“Shares”), directly held by Corriente Master Fund II, LP as of the date hereof.

    (2)

    Based on 35,324,607 Shares outstanding as of October 30, 2020, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2020.

     

    3


    CUSIP No.    14147L108

     

      1    

      Names of reporting persons

     

      Mark L. Hart III

      2  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC use only

     

      4  

      Citizenship or place of organization

     

      United States of America

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       5     

      Sole voting power

     

      0

       6   

      Shared voting power

     

      2,000,000 (1)

       7   

      Sole dispositive power

     

      0

       8   

      Shared dispositive power

     

      2,000,000 (1)

      9    

      Aggregate amount beneficially owned by each reporting person

     

      2,000,000

    10  

      Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

      ☐

    11  

      Percent of class represented by amount in Row (9)

     

      5.66% (2)

    12  

      Type of reporting person (see instructions)

     

      IN

     

    (1)

    Consists of 2,000,000 shares of common stock of the Issuer, par value $0.0001 per share (“Shares”), directly held by Corriente Master Fund II, LP as of the date hereof. Corriente Advisors, LLC acts as an investment adviser to, and manages investment and trading accounts of, Corriente Master Fund II, LP. Mr. Hart is the Chairman and Chief Executive Officer of Corriente Advisors, LLC. Mr. Hart may be deemed to indirectly beneficially own securities held by Corriente Master Fund II, LP.

    (2)

    Based on 35,324,607 Shares outstanding as of October 30, 2020, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2020.

     

    4


    Item 1(a)

    Name of issuer:

    Cardiff Oncology, Inc.

     

    Item 1(b)

    Address of issuer’s principal executive offices:

    11055 Flintkote Avenue, San Diego, California 92121

     

    Item 2(a)

    Name of person filing:

    This Schedule is being filed on behalf of each of the following persons (each, a “Reporting Person” and collectively, the “Reporting Persons”)

     

      i)

    Corriente Advisors, LLC (“Corriente Advisors”);

     

      ii)

    Corriente Master Fund II, LP (“Corriente Master Fund II”); and

     

      iii)

    Mark L. Hart III (“Mr. Hart”).

    This Schedule relates to shares of common stock of the Issuer, par value $0.0001 per share (“Shares”), directly held by Corriente Master Fund II. Corriente Advisors acts as an investment adviser to, and manages investment and trading accounts of, Corriente Master Fund II. Corriente Advisors may be deemed to indirectly beneficially own securities held by Corriente Master Fund II. Mr. Hart is the Chairman and Chief Executive Officer of Corriente Advisors. Mr. Hart may be deemed to indirectly beneficially own securities held by Corriente Master Fund II.

    Each Reporting Person declares that neither the filing of this Schedule nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act) with any other person as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any syndicate or group with respect to the Issuer or any securities of the Issuer.

     

    Item 2(b)

    Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is 1401 Foch St, Suite 100, Fort Worth, TX 76107.

     

    Item 2(c)

    Citizenship:

     

      i)

    Corriente Advisors is a Delaware limited liability company;

     

      ii)

    Corriente Master Fund II is a Cayman Islands limited partnership; and

     

      iii)

    Mr. Hart is a citizen of the United States of America.

     

    Item 2(d)

    Title of Class of Securities:

    Common Stock, par value $0.0001 per share

     

    5


    Item 2(e)  

    CUSIP No.:

    14147L108

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
    (b)    ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)    ☐ Insurance company defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)    ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)    ☒ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)    ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)    ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)    ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
    (j)    ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
    (k)    ☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ______________.

     

    Item 4.

    Ownership

     

    (a)

    Amount Beneficially Owned:

    As of the date hereof, each of the Reporting Persons may be deemed to be the beneficial owner of 2,000,000 Shares.

     

    6


    (b) Percent of Class:

    As of the date hereof, each of the Reporting Persons may be deemed to be the beneficial owner of approximately 5.66% of the Shares outstanding, based on 35,324,607 Shares outstanding as of October 30, 2020, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2020.

     

    (c)

    Number of shares as to which such person has:

    As of the date hereof, for each of the Reporting Persons:

     

      (i)

    Sole power to vote or to direct the vote: 0

     

      (ii)

    Shared power to vote or to direct the vote: 2,000,000

     

      (iii)

    Sole power to dispose or to direct the disposition of: 0

     

      (iv)

    Shared power to dispose or to direct the disposition of: 2,000,000

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    7


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 16, 2021

     

    CORRIENTE ADVISORS, LLC

    /s/ Matthew Gilman

    Chief Financial Officer
    CORRIENTE MASTER FUND II, LP

    /s/ Matthew Gilman

    Chief Financial Officer of Corriente Advisors, LLC, the Investment Manager of Corriente Master Fund II, LP
    MARK L. HART III

    /s/ Mark L. Hart III

     

    8


    EXHBIT INDEX

     

    Exhibit

            Page No.  
    A. Joint Filing Agreement      10  

     

     

    9

    Get the next $CRDF alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CRDF

    DatePrice TargetRatingAnalyst
    7/8/2025$19.00Buy
    Ladenburg Thalmann
    6/24/2025$3.50Hold
    Jefferies
    9/6/2024$8.00Buy
    Craig Hallum
    2/28/2022$26.00 → $25.00Buy
    HC Wainwright & Co.
    1/5/2022Outperform
    William Blair
    12/8/2021$19.00Outperform
    Robert W. Baird
    12/8/2021$19.00Outperform
    Baird
    8/10/2021$25.00 → $26.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CRDF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

      – Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development – – Company will hold a conference call on July 29 at 4:30 p.m. ET/1:30 p.m. PT to share additional clinical data from its randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer ("mCRC") – SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announc

      6/17/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

      – Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate – – The trial evaluated three doses of onvansertib in combination with paclitaxel, and objective responses were observed only at the highest dose of onvansertib – – The combination was well-tolerated and demonstrated a safe and manageable toxicity profile – SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced positive data from an investigator-initiated Phase 1b cli

      6/2/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

      - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer ("mCRC") - - Expanded intellectual property portfolio with second patent covering treatment of all bev-naïve patients, including RAS-mutated and RAS wild-type mCRC, across all lines of therapy - - Cash and investments of $79.9 million as of March 31, 2025, projected runway into Q1 2027 - SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial res

      5/8/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    SEC Filings

    See more
    • Cardiff Oncology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Cardiff Oncology, Inc. (0001213037) (Filer)

      6/26/25 4:30:47 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Cardiff Oncology, Inc. (0001213037) (Filer)

      6/17/25 4:15:28 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Cardiff Oncology Inc.

      EFFECT - Cardiff Oncology, Inc. (0001213037) (Filer)

      5/14/25 12:15:22 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann initiated coverage on Cardiff Oncology with a new price target

      Ladenburg Thalmann initiated coverage of Cardiff Oncology with a rating of Buy and set a new price target of $19.00

      7/8/25 8:35:06 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on Cardiff Oncology with a new price target

      Jefferies initiated coverage of Cardiff Oncology with a rating of Hold and set a new price target of $3.50

      6/24/25 8:00:04 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Craig Hallum initiated coverage on Cardiff Oncology with a new price target

      Craig Hallum initiated coverage of Cardiff Oncology with a rating of Buy and set a new price target of $8.00

      9/6/24 7:59:22 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Sidhu Roger

      3 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      7/8/25 4:05:06 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Tannenbaum Renee P

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      6/30/25 9:39:52 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Markin Rodney S

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      6/30/25 9:38:55 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Levine James E. bought $36,726 worth of shares (7,716 units at $4.76) (SEC Form 4)

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      12/18/24 4:37:28 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Tannenbaum Renee P bought $34,224 worth of shares (10,000 units at $3.42), increasing direct ownership by 100% to 20,000 units (SEC Form 4)

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      12/16/24 5:00:03 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Pace Gary W bought $940,199 worth of shares (361,615 units at $2.60), increasing direct ownership by 50% to 1,047,876 units (SEC Form 4)

      4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

      12/12/24 4:05:04 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Cardiff Oncology Inc. (Amendment)

      SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)

      2/6/24 4:01:34 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Cardiff Oncology Inc. (Amendment)

      SC 13G/A - Cardiff Oncology, Inc. (0001213037) (Subject)

      2/14/23 12:47:09 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Cardiff Oncology Inc.

      SC 13G - Cardiff Oncology, Inc. (0001213037) (Subject)

      1/26/23 1:30:22 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Financials

    Live finance-specific insights

    See more
    • Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

      – Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development – – Company will hold a conference call on July 29 at 4:30 p.m. ET/1:30 p.m. PT to share additional clinical data from its randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer ("mCRC") – SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announc

      6/17/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

      - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer ("mCRC") - - Expanded intellectual property portfolio with second patent covering treatment of all bev-naïve patients, including RAS-mutated and RAS wild-type mCRC, across all lines of therapy - - Cash and investments of $79.9 million as of March 31, 2025, projected runway into Q1 2027 - SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial res

      5/8/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

      SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it will hold a conference call on Thursday, February 27 after the close of trading to review financial results for the fourth quarter ended December 31, 2024. Conference Call and Webcast Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on February 27, 2025. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://investors

      2/20/25 4:05:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRDF
    Leadership Updates

    Live Leadership Updates

    See more
    • Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update

      First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with KRAS/NRAS-mutated Metastatic Colorectal Cancer (mCRC) Introduced full membership of Scientific Advisory Board (SAB) Announced appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer Cash, cash equivalents, and short-term investments of approximately $97 million as of March 31, 2023, projected runway into 2025 SAN DIEGO, May 4, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the first-q

      5/4/23 4:10:00 PM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer

      Brings world class capabilities and deep expertise in colorectal cancer and other solid tumor indications to advance the clinical development of onvansertib  Served as the lead investigator for two practice-changing trials of bevacizumab (Avastin®) combinations leading to the approval of bevacizumab in metastatic colorectal cancer (mCRC)1,2 SAN DIEGO, Feb. 2, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that it has strengthened its leadership team with the appointment of Fairooz Kabbinavar, MD, FACP, as

      2/2/23 8:00:00 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory Affairs

      SAN DIEGO, Jan. 11, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced the appointments of Tod Smeal, Ph.D., as chief scientific officer (CSO) and Charles Monahan, RPh, as senior vice president, regulatory affairs. "We are excited to welcome Tod and Charles to Cardiff Oncology as we approach key in

      1/11/22 8:00:00 AM ET
      $CRDF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care